INCY - Incyte Corporation
After hours:
| Previous close | 61.51 |
| Open | 61.50 |
| Bid | 62.52 x 800 |
| Ask | 62.53 x 800 |
| Day's range | 61.42 - 62.60 |
| 52-week range | 60.71 - 86.29 |
| Volume | |
| Avg. volume | 1,667,793 |
| Market cap | 13.952B |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | 43.13 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
WILMINGTON, Del., May 25, 2023--Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
- Business Wire
Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
WILMINGTON, Del., May 08, 2023--Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
- Business Wire
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
WILMINGTON, Del., May 02, 2023--Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
- Business Wire
Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream
WILMINGTON, Del., May 01, 2023--SCRATCH-AD Trial Demonstrates Substantial, Rapid Itch Reduction in Mild-Moderate Atopic Dermatitis Patients Treated with Opzelura (ruxolitinib) Cream
- Business Wire
Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
WILMINGTON, Del., April 20, 2023--European Commission Approves Opzelura (ruxolitinib) Cream asTreatment for Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
- Business Wire
Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del., April 18, 2023--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of May:
- Business Wire
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
BOSTON & WILMINGTON, Del., April 16, 2023--5-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
- Business Wire
Incyte to Report First Quarter Financial Results
WILMINGTON, Del., April 11, 2023--Incyte to Report First Quarter Financial Results
- Business Wire
Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
WILMINGTON, Del. & TOKYO, March 27, 2023--Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
- Business Wire
Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets
WILMINGTON, Del., March 24, 2023--Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets
- Business Wire
Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
WILMINGTON, Del., March 22, 2023--Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
- Business Wire
Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
WILMINGTON, Del., March 18, 2023--Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
- Business Wire
Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo
WILMINGTON, Del., March 18, 2023--Long-term Extension Data from TRuE-V Program Demonstrate Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo
- Business Wire
Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
WILMINGTON, Del., March 14, 2023--Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
- Business Wire
Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
WILMINGTON, Del., March 06, 2023--Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
- Business Wire
Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis
WILMINGTON, Del., March 03, 2023--Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis
- Business Wire
Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
WILMINGTON, Del., February 24, 2023--Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
- Business Wire
Incyte to Present at Upcoming Investor Conference
WILMINGTON, Del., February 16, 2023--Incyte (Nasdaq:INCY) announced today that it will present at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 11:10 a.m. (EST) in Boston.
- Business Wire
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
WILMINGTON, Del., February 10, 2023--Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
- Business Wire
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
WILMINGTON, Del., February 07, 2023--Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
- Business Wire
Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
WILMINGTON, Del., January 17, 2023--Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2022 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 7, 2023.
- Business Wire
Incyte’s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session
WILMINGTON, Del., December 11, 2022--Incyte’s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session
- Business Wire
Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022
WILMINGTON, Del., December 10, 2022--Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022
- Business Wire
Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia
WILMINGTON, Del. & HONG KONG, December 02, 2022--Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia
- Business Wire
Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors
WILMINGTON, Del. & SAN DIEGO, Calif., November 07, 2022--Incyte and Mirati Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in KRASG12C-Mutated Solid Tumors
